Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5844626 | 0.88 | HTR1A (0.67) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628542 | 0.86 | HTR1A (0.72) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL5843988 | 0.86 | HTR1A (0.63) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628786 | 0.86 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6629700 | 0.86 | HTR1A (0.65) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6627811 | 0.85 | HTR1A (0.68) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6628881 | 0.85 | HTR1A (0.61) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6626528 | 0.84 | HTR1A (0.69) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6767324 | 0.84 | HTR1A (0.71) | HTR1ASLC6A4KDM4ELMNAALOX15 | |
| SCHEMBL6333658 | 0.84 | HTR1A (0.66) | HTR1ASLC6A4KDM4ELMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559169-B2 | For therapy of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder,obsessive compulsive disorder, obesity, eating disorders, sexual dysfunction | WYETH | 2003-05-06 | — | — | US | claimed |
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2002-12-19 | — | — | US | claimed |
| US-7041683-B2 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1, 4-benzodiozan | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH | 2003-12-25 | — | — | US | disclosed |
| US-6559169-B2 | For therapy of depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder attention deficit disorder,obsessive compulsive disorder, obesity, eating disorders, sexual dysfunction | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193400-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | HTR1A 16/4885SLC6A4 185/4885KDM4E 1730/4885 |
| US-20030236241-A1 | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan | OPRD1, DRD1, DRD2 | HTR1A 16/4885SLC6A4 185/4885KDM4E 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.